RAPP (Rapport Therapeutics) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Rapport Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Rapport Therapeutics's long-term debt to total assets ratio declined from Dec. 2023 (0.01) to Dec. 2024 (0.00). It may suggest that Rapport Therapeutics is progressively becoming less dependent on debt to grow their business.

Rapport Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Rapport Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics LT-Debt-to-Total-Asset Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

0.01

Rapport Therapeutics Quarterly Data
	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			0.01	0.01	-	-	-

Rapport Therapeutics LT-Debt-to-Total-Asset Calculation

Rapport Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.739	/	314.933
	=

Rapport Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.739	/	314.933
	=

Rapport Therapeutics (NAS:RAPP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Rapport Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.